CFM
AUPH icon

Catalyst Funds Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Catalyst Funds Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,200
Closed -$38.1K – 397
2024
Q3 		$38.1K Buy
+5,200
New +$32.2K 0.01% 900

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Catalyst Funds Management's AUPH Position: Q4 2024 in Review

Catalyst Funds Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2024, closing a stake of 5,200 shares — an estimated $38.1K sold.

Catalyst Funds Management first reported a position in AUPH in Q3 2024 and held it in 1 quarter. The position peaked at $38.1K in Q3 2024. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

  • Catalyst Funds Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 5,200 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $38.1K.
  • Catalyst Funds Management first reported a position in Aurinia Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Catalyst Funds Management's Aurinia Pharmaceuticals position peaked at $38.1K in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.